Pfizer Venture Investments β Full Portfolio
179 tracked investments Β· listed companies and verified rows first
4DMT is a late-stage biotechnology company that develops gene delivery systems and genetic therapeutics targeting specific tissue types for various diseases.
BiotechHealthtechEmeryville, US
David Kirn(Executive Officer, Director)inDavid Schaffer(Director)inTheresa Janke(Executive Officer)in
BoardSharon Tetlow(Director)Margi McLoughlin(Director)
Co-investorsAmzak HealthBerkeley CatalystBOLD LongevityChiesi VenturesPappas CapitalCasdin Capital+1 more
Bolt Biotherapeutics is a clinical-stage biotech company developing novel immunotherapies that leverage innate immune system mechanisms to treat cancer.
BiotechHealthtechMedical DevicesSan Francisco, US
Dr. Edgar G. Engleman(Founder)
Co-investorsRA CapitalSamsara BioCapitalSofinnova VenturesVivo CapitalNan Fung Life SciencesNovo Holdings+1 more
Enliven Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops small molecule therapeutics using a precision medicine approach, with a focus on oncology and hematology.
BiotechHealthtechBoulder, US
Sam Kintz(Co-founder and Head of Pipeline)inJoe Lyssikatos(Co-founder and Research Fellow)Anish Patel(Co-founder and Chief Operating Officer)Rick Fair(Chief Executive Officer and Member of the Board of Directors)inHelen Collins(Chief Medical Officer)inBen Hohl(Chief Financial Officer and Head of Corporate Development)in
Co-investors5AM VenturesOrbiMedRoche Venture FundARCH Venture Partners
Ginkgo Bioworks builds autonomous labs that accelerate bioengineering for applications in pharmaceutical, agricultural, and industrial biotechnology.
AgTechAI & Machine LearningBiotechDeep TechHealthtechRoboticsBoston, US
Jason Kelly(Co-founder & CEO)inReshma Shetty(Co-founder, President & Chief Operations Officer)inBarry Canton(Foundry Technology Strategy & Direction)inAustin Che(Strategic Partnerships & Investments)inTom Knight(Founder, Ginkgo Fellow)
BoardReshma Sohoni
Co-investors11.2 CapitalAllen Institute for AI (AI2) IncubatorB3 HoldingCannage CapitalCool Climate CollectiveDCVC (Data Collective)+21 more
Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins.
BiotechDeep TechHealthtech
Nello Mainolfi(Founder)in
Co-investorsAtlas VentureAvoro Capital AdvisorsBain Capital Life SciencesBessemer Venture PartnersHatteras Venture PartnersMRL Ventures Fund+3 more
BiotechAustin, US
Matthew Winkler(Director)Sinil Kim(Executive Officer)inPaul Lammers(Executive Officer, Director)inJon Irvin(Executive Officer)Casi DeYoung(Executive Officer)
BoardMichael Powell(Director)
Co-investorsOrbiMed
Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.
BiotechBeltsville, US
Michael Richman(Executive Officer, Director)Timothy Mayer(Executive Officer)inUdayan Guha(Executive Officer)inSteven P. Cobourn(Executive Officer)inSourav Kundu(Executive Officer)inKevin Shaw(Executive Officer)in
Co-investorsBay City CapitalCanaan PartnersLAVLilly Asia VenturesQuan CapitalSofinnova Ventures+2 more
Novocure develops Tumor Treating Fields therapy for treating aggressive forms of cancer.
BiotechHealthtechMedical Devices
William F. Doyle(Executive Chairman)Frank Leonard(Chief Executive Officer)in
Co-investorsWindham Capital Partners
Synlogic develops synthetic biology-based biotherapeutics that use engineered living organisms to treat diseases.
BiotechDeep TechMedical DevicesCambridge, US
Bharatt Chowrira(Executive Officer)inMichael Sheahan(Executive Officer)Jose Carlos Gutierrez-Ramos(Executive Officer, Director)inPaul Miller(Executive Officer)inAoife Brennan(Executive Officer)inTodd Shegog(Executive Officer)in
Co-investorsAtlas VentureNew Enterprise Associates (NEA)NSG VenturesSofinnova VenturesSolasta VenturesOrbiMed
RefleXion Medical develops SCINTIX autonomous radiotherapy, an external beam theranostic oncology platform that uses biological signals from radiopharmaceutical-labeled cancer cells to deliver real-time, motion-managed radiation to lung and bone tumors from primary or metastatic disease.
BiotechHealthtechMedical DevicesHayward, US
Samuel Mazin(Executive Officer, Director)inAkshay Nanduri(Executive Officer, Director)in
BoardJay Watkins(Director)
Board seatRana Al-HallaqΒ· per SEC Form D
Co-investorsAscension VenturesCatalio Capital Management, LPSofinnova PartnersSonder CapitalVenrockSonder Futures
AMRA Medical is a global health informatics company specializing in MRI-based fat distribution and muscle composition analysis for precision medicine applications.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLinkΓΆping, SE
Magnus Borga(Co-Founder)inOlof Dahlqvist Leinhard(Chief Executive Officer, Co-Founder)in
Co-investorsHealthCap
Anaveon develops engineered antibodies targeting immune system regulatory nodes to treat autoimmune diseases by selectively eliminating or reprogramming pathogenic immune cells.
BiotechBasel, CH
Thaminda(Chief Business Officer)inLaetitia Pouzol(Chief Scientific Officer)in
Co-investorsNovartis Venture FundPontifax Venture Capital
Arkuda is an independent information platform that provides analysis and reviews of online gaming platforms operating in Azerbaijan, focusing on legal compliance, security protocols, and user protection for gaming platforms like Mostbet.
ConsumerGamingBaku, AZ
Co-investorsAtlas VentureMission BiocapitalPfizer VenturesPivotal Life Sciences
Arrakis Therapeutics develops RNA-targeted small-molecule (rSM) medicines, working independently and with partners to create drug candidates aimed at the root causes of disease.
AI & Machine LearningBiotechDeep TechHealthtechCambridge, US
Michael Gilman(Executive Officer, Director)inMark DeLong(CEO)inDavid Neafus(Executive Officer)inRussell C. Petter(Executive Officer)
BoardColleen Cuffaro(Director)inAlan E. Walts(Director)in
Co-investorsCanaan PartnersPfizer VenturesAdvent Life SciencesNextech InvestOUP (Osage University Partners)venBio Partners+1 more
Artios develops DNA damage response (DDR)-based medicines targeting patients with high unmet need cancers.
BiotechHealthtechMedical Devices
Co-investorsAndera PartnersM VenturesNovartis Venture FundRA CapitalSofinnova PartnersSV Health Investors+2 more
Co-investorsSV Health Investors
Autobahn Therapeutics develops orally administered small molecule prodrugs using a brain-targeting chemistry platform to create regenerative medicines for central nervous system (CNS) disorders.
BiotechDeep TechMedical DevicesSan Diego, US
Kevin Finney(Chairman, President and CEO)inJohn Borkholder(Executive Officer)in
BoardKristina Burow(Director)inThomas Cahill(Director)Timothy Anderson(Director)Philip J DeSouza(Director)
Co-investorsARCH Venture PartnersCanaan PartnersMonograph Capital PartnersSamsara BioCapitalNewpath Partners
Co-investorsBioAdvanceOUP (Osage University Partners)
Co-investorsPappas Capital
Developing bispecific antibodies for precision autoimmune applications
Co-investorsPathway Bioventures
BioNTech is a biotechnology company developing immunotherapies that use the body's immune system, combining multiple therapeutic modalities and biological targets to treat cancer, infectious diseases, and other serious conditions.
BiotechHealthtechMainz
Ozlem Tureci(Executive Officer)Ugur Sahin(Executive Officer)inSierk Poetting(Executive Officer)inSean Marett(Executive Officer)inRyan Richardson(Executive Officer)in
BoardChristoph Huber(Director)
Co-investorsManta Ray VenturesMIG Capital AGOnsight Ventures
BiotechSouth San Francisco, US
Wendye Robbins(Executive Officer, Director)
BoardLuke Evnin(Director)inCameron Wheeler(Director)Peter van Vlasselaer(Director)Elaine Jones(Director)William Slattery(Director)
Co-investorsBay City CapitalOUP (Osage University Partners)+ND CapitalDeerfield Management CompanyMPM BioImpactOsage University Partners
AbbVie is a biopharmaceutical company that discovers and delivers medicines for immune-mediated diseases and other therapeutic areas globally.
BiotechHealthtechMedical DevicesSan Diego, US
Adrian Bot(Executive Officer)Laura Shawver(Executive Officer, Director)inRamin Farzaneh-Far(Executive Officer)Justin Thacker(Executive Officer)Karen Smith(Director)Fabio Pucci(Director)
Co-investorsRA CapitalSofinnova VenturesVida Ventures
Cartography develops antibody-based cancer therapies using single-cell sequencing and computational biology to identify precise cellular targets.
AI & Machine LearningBiotechDeep TechMedical DevicesSouth San Francisco, US
Max Mumbach(Founding Scientist, Target Discovery)inJeffrey Verboon(Founding Scientist, Computational Biology)inAnsu Satpathy(Founder)Kevin Parker, PhD(Chief Executive Officer, Board Director; co-founder)Ansuman Satpathy, MD, PhD(Co-founder; Board Director)Howard Chang(Co-founder)in
Co-investors8VCAndreessen HorowitzArtis VenturesGlobal BioAccess FundHAWKTAILWing+6 more
Co-investorsFrazier Life Sciences
BiotechPittsburgh, US
Joshua M. Tarnoff(Executive Officer, Director)Diane Jorkasky(Chief Medical Officer)Federica O'Brien(Chief Financial Officer)
BoardI. Wistar Morris(Director)Kenji Harada(Director)Miwa Toyoda(Director)
Co-investorsAndera PartnersNew Enterprise Associates (NEA)HBM Healthcare InvestmentsScientific Health Development
Co-investorsDolby Family Ventures
Crossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Alexander Nolte(Executive Officer)inDmitri Wiederschain(Executive Officer)in
BoardAlexandra Cantley(Director)inSakae Asanuma(Director)inBriggs Morrison(Executive Officer, Director, Promoter)inIrena Melnikova(Director)in
Co-investorsMPM BioImpactBiotechnology Value FundMirae Asset Venture InvestmentPfizer VenturesPolaris PartnersTaiho Ventures, LLC
Curve Therapeutics uses its mammalian cell-based Microcycle discovery platform to develop cyclic peptide and small molecule drugs against intracellular targets.
AI & Machine LearningBiotech
Co-investorsEpidarex CapitalColumbus Venture Partners
BiotechCambridge, US
Christoph M. Adams(Executive Officer, Director)James McArthur(Executive Officer)
BoardDavid Mott(Director)Mette Kirstine Agger(Director)Barbara Dalton(Director)Sandip Agarwala(Director)
Co-investorsAlexandriaLongitude CapitalNew Enterprise Associates (NEA)
CytomX is a clinical-stage biopharmaceutical company developing conditionally activated biologic cancer therapies, including antibody-based treatments designed to target tumors while limiting effects on healthy tissue.
BiotechHealthtech
Sean A. McCarthy(Chief Executive Officer and Chairman)inMarcia P. Belvin(SVP, Chief Scientific Officer)inDawn Benson(SVP, Quality and Product Manufacturing)inWayne Chu(Chief Medical Officer)Rachael Lester(SVP, Chief Business Officer)inChris Ogden(Chief Financial Officer)in
Co-investorsCanaan PartnersLongitude CapitalOrbiMed
DEM BioPharma is a biotechnology company developing cancer therapies by targeting the immune system, drawing on genetic and immuno-oncology research.
BiotechHealthtechCambridge, US
Nenad Grmusa(Chief Executive Officer)inJohn McCabe(Chief Financial and Operating Officer)
Co-investorsAlta PartnersAstellas Venture Management LLCDC Investment PartnersLongwood FundUTokyo Innovation Platform Co. Ltd.Insight Partners+1 more
Acquired by Fluidigm/Standard BioTools.
Co-investorsFACIT (Fight Against Cancer Innovation Trust)
eFFECTOR Therapeutics was a clinical-stage biopharmaceutical company.
BiotechSolana Beach, US
Stephen F. Worland, Ph.D.(Executive Officer, Director)Alana McNulty(Executive Officer)in
BoardSimeon George(Director)Jonathan Root(Director)inKen Haas(Director)Laurence Lasky(Director)
Co-investorsAstellas Venture Management LLCMission Bay CapitalMission BiocapitalOUP (Osage University Partners)US Venture PartnersSofinnova Ventures
BiotechSanta Clara, US
Jeffrey Glenn(Director)David Cory(Executive Officer, Director)
BoardNina Kjellson(Director)inEd Engleman(Director)
Co-investorsCanaan PartnersVivo Capital
Co-investorsM VenturesRA Capital
Enlaza Therapeutics develops covalent protein therapeutics using its War-Lock technology, which incorporates proprietary unnatural amino acids into protein drugs so they form irreversible covalent bonds with disease-related targets.
BiotechDeep TechSan Diego, US
Sergio Duron(Co-Founder & Chief Executive Officer)inSanford Madigan(Co-Founder, President & Chief Business Officer)inAnaleah Heidt(Chief Scientific Officer)in
BoardMarcos Milla(Director)Jay Lichter(Director)Tighe Reardon(Executive Officer)
Co-investorsFrazier Life SciencesLightspeed Venture PartnersSamsara BioCapitalAvalon BioVenturesPappas CapitalJ.P. Morgan Asset Management+1 more
Medtronic designs and develops medical technology for treating complex diseases.
AI & Machine LearningDigital HealthHealthtechMedical Devices
Co-investors8VCCWRU Technology VenturesElevate VenturesMenlo VenturesOak Investment PartnersQuesta Capital+5 more
BiotechBranford, US
Donmienne Leung(Manager)Ian Taylor(Manager)Stephen Bloch(CEO and Manaager)
BoardDerek Yoon(Manager)Jasmina Marjanovic(Manager)inDenis Patrick(Manager)
Co-investorsSolasta VenturesTakeda Ventures
Flare Therapeutics develops small molecule medicines targeting transcription factors using a chemistry and proteomics platform that enables ligand discovery directly from cells.
AI & Machine LearningBiotechDeep TechHealthtech
Jim Audia(Executive Vice President, Drug Discovery and Early Development, and Founding Scientist)Jacob Stuckey(Senior Director, Biochemistry and Chemical Biology, and Founding Scientist)in
Co-investorsNexTech VenturesPfizer VenturesThird Rock VenturesNextech InvestShangBay Capital LLCAgent Capital
FoRx Therapeutics is a biotechnology company focused on oncology drug discovery and clinical development, targeting the DNA Damage Response (DDR) network with small molecule inhibitors.
BiotechDeep TechHealthtechBasel, CH
Tarig Bashir(Chief Executive Officer (CEO))inJens WΓΌrthner(Chief Medical Officer (CMO))Frank Zenke(Chief Scientific Officer (CSO))in
Co-investorsM VenturesNovartis Venture Fund
Genomic Health develops diagnostic tests and related services and runs health-equity initiatives aimed at improving access, awareness, and outcomes for patients and communities, including uninsured and underinsured populations.
BiotechDigital HealthHealthtechMedical Devices
Steve Shak(Founder)inKevin Conroy(CEO)in
Co-investorsKleiner PerkinsVedanta Capital
Greywolf is a clinical-stage biotech developing antigen modulation therapies, including oral small molecules in Phase 1/2 trials, for people with cancers and autoimmune disorders.
BiotechDigital HealthHealthtechMedical DevicesOxford, GB
Peter Joyce(Co-founder)inTom McCarthy(Co-founder)in
Co-investorsAndera PartnersCanaan PartnersOxford Science EnterprisesBritish Patient CapitalEarlybird Venture CapitalPfizer Ventures
Co-investorsLAVLilly Asia Ventures
ImCheck Therapeutics develops next-generation immunotherapeutic antibodies targeting the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules for immune system modulation.
BiotechHealthtech
Co-investorsAndera PartnersKurma PartnersPureos BioventuresAgent CapitalGimv
Immunocodex develops lipid nanoparticle mRNA-based therapies targeting dendritic cells to induce immune tolerance for the treatment of autoimmune diseases.
AI & Machine LearningBiotechHealthtechLongevityMedical DevicesBoston, US
Mark Carthy(Founder and CEO)Francisco J. Quintana(Scientific Founder)
Immunos Therapeutics develops therapies for immuno-oncology and inflammatory diseases.
BiotechHealthtechMedical Devices
Co-investorsBioMedPartnersLightspeed Venture PartnersMission BiocapitalPfizer Venturesredalpine
BiotechPhiladelphia, US
Philip R. Johnson, M.D.(Executive Officer, Director)inDora Mitchell(Executive Officer)Lori Forrest(Executive Officer)Leon Moulder, Jr.(Director)Benjamin Lund(Director)
BoardTomas Kiselak(Director)
Co-investorsOUP (Osage University Partners)Agent CapitalBain Capital Life SciencesLongwood FundOsage University PartnersPfizer Ventures+2 more
Clinical-stage biotech using its RAPID chemoproteomics platform to drug challenging targets; acquired by Otsuka in 2024.
Boston, US
Co-investorsAvalon BioVenturesBain Capital Life SciencesRA Capital
Clinical-stage Boston biotech developing oral pan-KRAS inhibitors for patients with KRAS-driven cancers.
BiotechBoston, US
Frank G. Haluska(Executive Officer, Director)in
BoardOmar Khalil(Director)Nicholas Saccomano(Director)Barbara Sosnowski(Director)Andrew Phillips(Director)Denis Patrick(Director)
Co-investorsSection 32
BiotechNew York, US
David Pompliano(Executive Officer)David McElligott(Executive Officer, Promoter)
BoardDavid Schubert(Executive Officer, Promoter)Joel Marcus(Director)Lindsay Rayle(Executive Officer, Promoter)Barbara Dalton(Director)
Co-investorsAbbVieAlexandriaARCH Venture PartnersDigitalis Ventures
BiotechNew York, US
M. Johnston Erwin(Director)Ian Howes(Executive Officer)Thong Le(Executive Officer, Director)David Schubert(Executive Officer)Kendall Mohler(Executive Officer)
BoardBarbara Dalton(Director)
Co-investorsACCELERATOR LIFE SCIENCE PARTNERS
Following a 2025 merger of Mallinckrodt and Endo, the combined business separated into two companies: Keenova Therapeutics, which develops treatments for rare, stigmatized, or unaddressed conditions across areas such as immunology, urology, hepatology, ophthalmology, orthopedics, and critical care; and Par Health, which produces generics, sterile injectables, and active pharmaceutical ingredients backed by a U.S.-based manufacturing network.
Advanced ManufacturingBiotechHealthtechMedical Devices
Co-investorsARCH Venture PartnersCross Creek AdvisorsSignet Healthcare PartnersSofinnova Ventures
Mediartx develops novel therapies for patients with fibrotic diseases.
BiotechMedical DevicesBoston, US
Rahul Ballal, PhD(CEO)Paul Yaworsky, PhD(CSO)inRahul Ballal(Executive Officer, Director)inBrian Hubbard(Director)Stacey Brenner(Executive Officer)David de Graaf(Director)
Co-investorsLongwood FundMission BiocapitalNovartis Venture FundOno Venture Investment, Inc.ShangBay Capital LLCSofinnova Partners+2 more
Day One (part of Servier) is a biopharmaceutical company developing targeted oncology medicines, with a focus on cancers affecting patients of all ages, including pediatric low-grade glioma (pLGG).
BiotechHealthtechCambridge, US
MICHAEL J. KAUFMAN(Executive Officer)inDonald Bergstrom(Executive Officer)ANNA PROTOPAPAS(Executive Officer, Director)Timothy Lowinger(Executive Officer)Eva Jack(Executive Officer)Wayne Foster(Executive Officer)
Co-investorsBain Capital Life SciencesF-Prime CapitalLightstone VenturesNew Enterprise Associates (NEA)Nextech InvestRho Ventures
Merus develops multispecific antibodies (Biclonics and Triclonics) that bind multiple cancer antigens to treat oncology indications.
BiotechMedical DevicesUtrecht, NL
Ton Logtenberg(Executive Officer, Director)inMark Throsby(Executive Officer)inHui Liu(Executive Officer)inJohn Crowley(Executive Officer)inL. Andres Sirulnik(Executive Officer)inLex Bakker(Executive Officer)in
Co-investorsAvoro Capital AdvisorsRA CapitalSofinnova Ventures
Co-investorsPontifax Venture Capital
BiotechKingston, US
Robert B. Nelson(Executive Officer, Director)Frank S. Menniti(Executive Officer, Director)inStevin Zorn(Executive Officer, Director)inIsaac Stoner(CEO)in
BoardRichard G. Horan(Director)Reetika Bhardwaj(Director)
Co-investorsDolby Family VenturesPfizer VenturesSlater Technology Fund
Mission Therapeutics develops therapeutics targeting deubiquitylating enzymes (DUBs), such as USP30, which regulate ubiquitylation and processes including mitophagy and protein homeostasis.
BiotechHealthtech
Co-investorsRoche Venture FundSofinnova PartnersSR One Capital Management
BiotechNew York, US
Nicholas Hertz(Director)Doug Crawford(Director)Daniel de Roulet, Jr.(Executive Officer, Director)
BoardJohannes Fruehauf(Director)
Montis Biosciences develops anti-C1q antibodies that target both the complement and myeloid axes to treat neuroinflammatory, autoimmune, neurodegenerative and ophthalmic diseases, with a lead program in Guillain-BarrΓ© syndrome and a second CD93 program in lung squamous cell carcinoma.
BiotechHealthtechLeuven, BE
Federico Grossi(Clinical Advisor & Acting CMO)
Co-investorsDroia VenturesPfizer VenturesVIB
Mozart Therapeutics develops protein therapeutics focused on immunology and oncology treatments.
BiotechMedical Devices
Mark Davis(Scientific Co-Founder)K. Christopher Garcia(Scientific Co-Founder)Calvin Kuo(Scientific Co-Founder)Katie Fanning(President & Chief Executive Officer)in
Co-investorsARCH Venture PartnersJDRF T1D FundMRL Ventures FundOno Venture Investment, Inc.Sofinnova PartnersAlexandria+3 more
NexImmune is a biotechnology company developing antigen-directed immunotherapies based on its proprietary AIM nanoparticle platform, which mimics dendritic cell signaling to activate antigen-specific T cell responses.
BiotechMedical DevicesGaithersburg, US
Jonathan Schneck(Director)Alain Cappeluti(Executive Officer, Director)Kenneth Carter(Executive Officer, Director)
BoardJanis Naeve(Director)James Barrett(Director)
Co-investorsRapha Capital Management, LLCNew Enterprise Associates (NEA)
Harnesses cutting-edge technologies to design exquisitely selective small molecule therapeutics.
Co-investorsAccess BiotechnologyBain Capital Life SciencesLightstone VenturesRA CapitalSV Health Investors
Normunity develops biologic anti-cancer therapies that act at the interface of the immune system and tumors, targeting mechanisms tumors use to evade immune surveillance.
BiotechHealthtech
Rachel Humphrey(Founding Chief Executive Officer)inLieping Chen(Scientific Founder)Mitchell Keegan(Chief Development Officer)inWilliam LaRochelle(Chief Scientific Officer)inStacy M. Plum(Chief Technology Officer)
Co-investorsSanofi VenturesTaiho Ventures, LLCPfizer VenturesSamsara BioCapitalCanaan PartnersConnecticut Innovations+3 more
Quince Therapeutics is a clinical-stage biopharmaceutical company developing eDSP, an investigational therapy studied in a Phase 3 clinical trial (NEAT) for patients with Ataxia-Telangiectasia (A-T).
BiotechHealthtechWest Lafayette, US
Philip S. Low, Ph.D.(Executive Officer, Director)David Lamond(Director)Daniel Hasler(Director)Dirk Thye, M.D.(Executive Officer, Director)William J. Rutter(Director)Alex Andrianopoulos(Director)
Co-investorsBreakout VenturesElevate Ventures
Nucleome develops 3D genomics technology to map genetic variants in the non-coding genome to the genes they dysregulate, with applications in understanding inflammatory diseases and discovering therapeutic targets.
AI & Machine LearningBiotechDeep Tech
Co-investorsM VenturesOxford Science EnterprisesBritish Patient CapitalJJDCPfizer Ventures
BiotechNew York, US
Brian O'Callaghan(Executive Officer, Director)David Renas(Executive Officer)Albert Yu(Executive Officer, Promoter)David McElligott(Executive Officer, Promoter)
BoardSteve Gillis(Director)Joel Marcus(Director)
Co-investors180 Degree CapitalAbbVieAlexandriaARCH Venture PartnersJohnson & Johnson Innovation β JJDC
BiotechCambridge, US
Robert Prentiss(Executive Officer)Ronald C. Renaud, Jr.(Executive Officer, Director)Thomas McCauley(Executive Officer)
BoardBrian Gallagher(Director)Jean- Francois Formela(Director)inJoshua Resnick(Director)
Co-investorsAtlas Venture
ReCode develops mRNA and gene correction therapeutics for genetic diseases, using proprietary lipid nanoparticle technology to deliver treatments to specific organs.
AI & Machine LearningBiotechHealthtechMedical DevicesMenlo Park, US
Dr. Daniel J. SiegwartArthur E Johnson(Executive Officer, Director)
Co-investorsAju IB Invesment CorporationEcoR1 CapitalEvolution VC PartnersMPM BioImpactOrbiMedOUP (Osage University Partners)+6 more
Resilience is a contract development and manufacturing organization (CDMO) that manufactures complex pharmaceutical products and active pharmaceutical ingredients to broaden access to medicines and protect biopharmaceutical supply chains against disruption.
Advanced ManufacturingBiotechEnterprise SoftwareBlue Ash, US
William S. Marth(Chief Executive Officer)
BoardRobert Nelsen
Co-investors8VCARCH Venture PartnersCatalio Capital Management, LPGV (Google Ventures)Koch Disruptive TechnologiesLux Capital+4 more
Rhythm Therapeutics develops precision medicines for rare neuroendocrine diseases, particularly those affecting the melanocortin-4 receptor pathway.
BiotechDigital HealthHealthtechMedical DevicesBoston, US
Keith Gottesdiener(Executive Officer, Director)inBart Henderson(Mr. Henderson is the President and Treasurer of the Issuer.)inDavid Meeker(President and Chief Executive Officer)in
BoardEdward T. Mathers(Director)inJonathan Silverstein(Director)inNeil Exter(Director)in
Co-investorsForesite CapitalHEALTHCARE ROYALTY PARTNERSNew Enterprise Associates (NEA)OrbiMedThird Rock Ventures
Saama provides AI-based data analytics solutions and services for the life sciences industry, with a focus on accelerating clinical trials.
AI & Machine LearningData & InfrastructureDigital HealthHealthtechSaaSCampbell, US
Suresh Katta(Executive Officer, Director)inSimon Ho(Executive Officer)in
BoardMarc McMorris(Director)inKen Coleman(Director)Dan Fishback(Director)William Binch(Director)
Co-investorsCarrick Capital PartnersMcKesson Ventures
Co-investorsLifeforce CapitalDigitalis Ventures
Simcha is a biotechnology company developing new cancer medicines based on immune biology research.
BiotechHealthtechNew Haven, US
Aaron Ring(Executive Officer, Director)inBeatrice McQueen(Chief Operating Officer)inSanuj Ravindran(Chief Executive Officer)Jeremy Barton(Chief Medical Director)Hirdesh Uppal(Senior Vice President Translational Research and Development Sciences)Joseph Catino(Executive Officer)
Co-investorsConnecticut InnovationsSR One Capital ManagementAxial VCBiotechnology Value FundRock Springs CapitalSamsara BioCapital
HealthtechStamford, US
Daniel S. Lynch(Executive Officer, Director)inSaqib Islam(Executive Officer, Director)Michael Greco(Executive Officer)
BoardStephen Squinto(Director)inDeval Patrick(Director)Carl L Gordon(Director)in
Co-investorsBain Capital Life SciencesOrbiMed
SpringWorks is a biotechnology company focused on developing innovative treatments for cancer patients.
BiotechDigital HealthHealthtechMedical DevicesAustin, US
Co-investorsFrazier Life Sciences
Qiagen manufactures enzymes and molecular biology products, plus scientific research tools and software for studying biological targets and pathways.
BiotechData & InfrastructureDigital HealthHealthtechMedical Devices
Co-investorsHarmonic Growth PartnersYsios Capital
STORM Therapeutics is a clinical-stage biotechnology company developing small molecule drugs that target RNA modifying enzymes to reprogram cells through RNA biology.
BiotechHealthtechMedical Devices
Co-investorsCambridge Innovation CapitalFast Track InitiativeM VenturesSeroba Life SciencesTaiho Ventures, LLCUTokyo Innovation Platform Co. Ltd.+1 more
Strata Oncology develops precision oncology biomarkers and predictive diagnostic tools for cancer treatment, including treatment response scores for antibody-drug conjugates (ADCs) and an Immunotherapy Response Score for anti-PD-1/PD-L1 therapies.
AI & Machine LearningBiotechDigital HealthMedical DevicesAnn Arbor, US
Daniel Rhodes(Executive Officer, Director)Matthew Martin(Executive Officer)Jeffrey Williams(Executive Officer, Director)
BoardChristopher O'Donnell(Director)inDavid Rubin(Director)inJames Pavlik(Director)in
Co-investorsArboretum VenturesDeerfield Management CompanyMerck Global Health Innovation FundPfizer Ventures
Co-investorsNew Enterprise Associates (NEA)
TRexBio develops biologic medicines targeting inflammation in autoimmune and inflammatory diseases by decoding human tissue biology.
AI & Machine LearningBiotechDeep TechHealthtech
Johnston Erwin(Chief Executive Officer)Ali Zarrin(Chief Scientific Officer)
Co-investorsAvego BioScience CapitalDelos CapitalAgent Capital
Biotech decoding human tissue immune biology to create therapeutics.
Co-investorsAvego BioScience CapitalSV Health Investors
Co-investorsLightspeed Venture Partners
Platform company targeting selective clearance of intracellular protein aggregates in neurodegenerative disease.
Co-investorsCambridge Innovation CapitalM VenturesStart Codon
Co-investorsCTI Life Sciences Fund L.P.Sofinnova Partners
TRIMTech Therapeutics is a biotechnology company focused on drug discovery and development, backed by investors including Cambridge Innovation Capital and BGF.
BiotechDeep TechLongevityMedical DevicesCambridge, GB
Damian Crowther, PhD FRCP(Co-founder, Head of Research)Dr. Leo James(Co-founder, Group Leader at MRC Laboratory of Molecular Biology)Dr. William McEwan(Co-founder, Group Leader at UK Dementia Research Institute, University of Cambridge)Nicki Thompson, PhD(CEO)Nicki Thompson(CEO)
Co-investorsCambridge Innovation CapitalPfizer VenturesSV Health Investors
Ablexis develops the AlivaMab Mouse, a transgenic mouse platform for antibody drug discovery used by major pharmaceutical companies.
BiotechDeep Tech
Larry(CEO and Founder)
Co-investorsCalifornia Technology Ventures
Adapsyn Bioscience is a biotech company focused on discovering and developing microbial natural product small molecules for therapeutic applications by leveraging genomic and chemical biology approaches.
AI & Machine LearningBiotechDeep TechHamilton, CA
Nathan Magarvey(Founder)
Co-investorsGenesys Capital
Aquinnah Pharmaceuticals develops oral small-molecule therapeutics targeting pathologic biomolecular condensates, such as stress granules formed by RNA-binding proteins, to slow neurodegenerative diseases including ALS and Alzheimer's disease.
BiotechHealthtechLongevity
Benjamin Wolozin(CSO & Co-founder)
Co-investorsTCG CrossoverM Ventures
Autifony Therapeutics is a privately funded biopharmaceutical company developing treatments for neurological conditions including Fragile X Syndrome and orphan epilepsy syndromes.
BiotechHealthtechMedical DevicesStevenage, GB
Charles H. Large(Founder and Chief Executive Officer)Giuseppe Alvaro(Director)Daniel UmbrichtBarbara Domayne-HaymanMartin GunthorpeHannah Selin
Co-investorsTectonic Ventures
BioAtla develops novel monoclonal antibody and cell-based therapeutics for cancer treatment using proprietary platforms including Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!).
BiotechHealthtechMedical DevicesSan Diego, US
BioNTech develops immunotherapies that use the body's immune system to treat cancer, infectious diseases, and other serious illnesses.
BiotechHealthtech
Co-investorsHM Venture PartnersSalvia
BlueLight Therapeutics develops novel drug molecules using a proprietary structure-based discovery platform targeting high-value therapeutic targets in life sciences.
AI & Machine LearningBiotechDeep TechSouth San Francisco, US
Ariel G. Notcovich(Founder & CEO)Mark Gallop(CSO)Mira Chaurushiya(CBO)Anjanabha Saha(VP, Discovery)
Co-investors5AM VenturesPfizer Ventures
Enara Bio discovers and validates Dark Antigens from non-coding genomic regions to identify novel cancer targets, and develops first-in-class bispecific T-cell engagers against these targets through its EnTiCE platform.
BiotechDeep TechMedical Devices
George Kassiotis(Co-founder)Drew Pardoll(Co-founder)Houman Ashrafian(Co-founder)
Co-investorsPfizer VenturesRA CapitalSamsara BioCapitalSV Health InvestorsM Ventures
Enodia Therapeutics develops small-molecule therapies that target protein degradation at the point of synthesis using a machine learning-enabled platform.
AI & Machine LearningBiotechDeep Tech
Yves Ribeill(CEO)
Co-investorsBpifranceElaiaPfizer Ventures
EvolveImmune develops immunotherapy treatments for cancer patients.
BiotechHealthtechMedical Devices
Stephen Bloch(Co-founder and Chief Executive Officer)Jay Fine(President, Research and Development)
Co-investorsSolasta VenturesPfizer Ventures
G-CON designs, manufactures, and installs prefabricated cleanroom systems for the biopharmaceutical, cell and gene therapy, and advanced therapy industries.
Advanced ManufacturingBiotechCleantechConstruction TechHardware
Robert Pedersen(Chief Executive Officer)
Co-investorsWP Global Partners
Co-investorsBreakout VenturesTaiho Ventures, LLC
Co-investorsDC Investment PartnersLongwood FundQuan CapitalAgent Capital
Jnana has developed RAPID, a next-generation chemoproteomics platform that enables rapid discovery of small molecule drugs targeting previously inaccessible disease targets by identifying novel binding sites on complex proteins.
AI & Machine LearningBiotechDeep TechAustin, US
Co-investorsAvalon BioVentures
Kestrel Therapeutics develops targeted cancer therapies focused on inhibiting KRAS mutations across all tumor types using structure-based drug design.
BiotechDigital HealthHealthtechMedical Devices
Frank(Founder, President & CEO)
Co-investorsKeiretsu ForumTSVC
Levicept is a company in the life sciences sector with backing from prominent healthcare and pharmaceutical investors including Medicxi, Pfizer Ventures, Gilde Healthcare, and Advent Life Sciences.
BiotechHealthtechMedical Devices
Simon Westbrook(Founder and CSO)
Co-investorsAdvent Life SciencesGilde HealthcareIndex VenturesMedicxiPfizer Ventures
MindImmune develops therapeutics targeting the immune drivers of neurodegenerative diseases such as Alzheimer's, focusing on immune cells that respond to amyloid plaques before they enter the brain.
BiotechHealthtech
Co-investorsSlater Technology FundDolby Family Ventures
Co-investorsMission Bay Capital
Montis Biosciences is a biotechnology company developing anti-C1q antibodies that target both the complement and myeloid axes to treat neuroinflammatory, autoimmune, neurodegenerative and ophthalmic diseases, with a lead program in Guillain-BarrΓ© syndrome.
BiotechHealthtechLeuven, BE
Federico Grossi(Clinical Advisor & Acting CMO)
Co-investorsDroia VenturesPfizer VenturesVIB
Co-investorsEcoR1 Capital
Nimbus Therapeutics is a biotechnology company that designs precision small molecule medicines using a computational, multidisciplinary drug discovery approach.
AI & Machine LearningBiotechDeep TechHealthtech
Co-investorsAtlas VentureLightstone Ventures
Palleon Pharma develops small molecule and biologic drugs targeting autoimmune and inflammatory diseases using proprietary glycoscience platforms.
BiotechDigital HealthMedical Devices
Jim Broderick(Co-Founder)Li Peng(Chief Scientific Officer)Stefani Wolff(Chief Development Officer)
Co-investorsMatrix Capital ManagementPfizer Ventures
PrescriberPoint operates an AI-enabled medication access platform that helps clinicians get patients onto prescribed therapies by providing prescribing support, coverage and cost-savings lookups in one place.
AI & Machine LearningDigital HealthHealthtechSaaS
Pyxis Oncology develops antibody-drug conjugates and immunotherapies targeting difficult-to-treat cancers to improve patient outcomes.
BiotechDigital HealthHealthtechMedical Devices
Co-investorsLongwood FundAgent Capital
TRIANA Biomedicines is a venture-backed biopharmaceutical company developing small-molecule "molecular glue" therapeutics that induce protein:protein interactions to degrade or alter disease-causing target proteins, with an initial focus on targeted protein degradation for cancer.
BiotechDeep TechHealthtechLexington, US
Patrick Trojer(President & CEO, Co-founder)
Co-investorsAtlas VentureAscenta CapitalBessemer Venture PartnersLightspeed Venture PartnersPfizer VenturesRA Capital
VitaDAO is a decentralized autonomous organization that funds and coordinates longevity and aging research using AI agents, decentralized governance, and on-chain funding mechanisms such as IP-NFTs.
BiotechCrypto & Web3Longevity
Co-investorsCollab+CurrencySora VenturesTioga Capital Partners
Vivet Therapeutics is a clinical-stage biotechnology company developing recombinant adeno-associated virus (rAAV) gene therapies for rare, inherited metabolic diseases, including Wilson's Disease and cerebrotendinous xanthomatosis.
BiotechHealthtechParis, FR
Co-investorsHealthCapKurma PartnersNovartis Venture FundRoche Venture FundYsios CapitalColumbus Venture Partners+1 more
Co-investorsNew Enterprise Associates (NEA)
HealthtechBoston, US
N. Anthony Coles(Executive Officer, Director)Richard Peters(Executive Officer, Director)Paulash Mohsen(Executive Officer)Brigitte Robertson(Executive Officer)Richard A. Heyman(Director)Jeffery W. Kelly(Director)
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.